ADC Therapeutics begins dosing in ADCT-402 Phase I trial for B-NHL patients

Swiss firm ADC Therapeutics (ADCT) has started a Phase I trial of its antibody drug conjugate (ADC) ADCT-402 in patients with relapsed or refractory B-cell non-Hodgkin Lymphoma (B-NHL).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news